>

Etienne Davignon - Gilead Sciences Independent Director

<div class='circular--portrait' style='background:#FCD202;color: white;font-size:3em;padding-top: 40px;;'>GIL</div>
GILD -- USA Stock  

Earning Report: 7th of May 2020  

  Director
Viscount Etienne F. Davignon is no Longer Independent Director of Gilead Sciences Inc. He is currently Minister of State for Belgium and serves as Chairman of Recticel CMB SN Air Holding and Genfina. Previously he served as Chairman of Socit Gnrale de Belgique a diversified financial and industrial company
Age: 82        
650 574-3000  www.gilead.com
Davignon has served as the European Community?s Commissioner for Industry and International Markets and as the EC?s Vice President for Research, Industry and Energy Policies. He served as Chairman of Recticel, CMB, SN Air Holding and Genfina and previously serving as Chairman of Soci?t? G?n?rale de Belgique. International background and significant policymaking and government experience, including serving as the Minister of State and previously serving as the EC?s Commissioner for Industry and International Markets and as the EC?s Vice President for Research, Industry and Energy Policies. Breadth of knowledge about Gilead?s business as a result of service on Gilead?s Board since 1990.

Management Efficiency

The company has return on total asset (ROA) of 0.13 % which means that it generated profit of $0.13 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 0.34 % meaning that it created $0.34 on every $100 dollars invested by stockholders.
The company currently holds 28.84 B in liabilities with Debt to Equity (D/E) ratio of 139.1 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Gilead Sciences has Current Ratio of 3.0 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

James KiltsPfizer
2007
Stacey CartwrightGlaxoSmithKline PLC
2011
Ann FudgeNovartis AG
2008
Alan LacyBristol Myers Squibb Company
2008
Kathi SeifertEli Lilly And Company
1995
Baroness VaderaAstrazeneca PLC
2011
David HooverEli Lilly And Company
2009
Michel DemareAstrazeneca PLC
2019
Joseph BoccuziAllergan Plc
2017
Stephanie BurnsGlaxoSmithKline PLC
2007
Ian DavisJohnson Johnson
2010
James BloemAllergan Plc
2013
Theodore SamuelsBristol Myers Squibb Company
2017
Hubert JolyJohnson Johnson
2019
Srikant DatarNovartis AG
2003
Mary CoeMerck Company
2019
Marcus WallenbergAstrazeneca PLC
1999
Robert KidderMerck Company
2005
Craig ThompsonMerck Company
2008
Carol DavidsonAllergan Plc
2018
Ellen MarramEli Lilly And Company
2013

Company Summary

Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company was founded in 1987 and is headquartered in Foster City, California. Gilead Sciences operates under Drug ManufacturersGeneral classification in USA and is traded on BATS Exchange. It employs 11800 people.Gilead Sciences (GILD) is traded on BATS Exchange in USA. It is located in 333 Lakeside Drive, Foster City, CA 94404, United States and employs 11,800 people. Gilead Sciences is listed under Pharmaceutical Products category by Fama And French industry classification.

Gilead Sciences Leadership Team

Kathleen Watson, Executive Vice President - Human ResourcesView
John McHutchison, Executive Vice President - Clinical ResearchView
Andrew Cheng, Executive Vice President - HIV Therapeutics and Development OperationsView
John Martin, Chairman and CEOView
Andrew Dickinson, Executive Vice President - Corporate Development and StrategyView
Gayle Wilson, Independent DirectorView
Daniel ODay, Chairman of the Board, CEOView
Jacqueline Barton, DirectorView
Brett Pletcher, Executive VP and General CounselView
William Lee, Executive Vice President - ResearchView
John Madigan, Independent DirectorView
Martin Silverstein, Executive Vice President - StrategyView
Kevin Lofton, Independent DirectorView
Paul Carter, Executive Vice President - Commercial OperationsView
Gregg Alton, Executive VP of Corporate and Medical Affairs and SecretaryView
Diana Brainard, Senior Vice President HIV and Emerging Viral InfectionsView
Carla Hills, Independent DirectorView
John Cogan, Lead Independent DirectorView
John Milligan, Pres and COOView
Nicholas Moore, Independent DirectorView
James Meyers, Executive Vice President - Worldwide Commercial OperationsView
Katie Watson, Executive Vice President of Human ResourcesView
Kelly Kramer, DirectorView
Johanna Mercier, Chief Commercial OfficerView
Jyoti Mehra, Executive Vice President of Human ResourcesView
Laura Hamill, Executive Vice President - Worldwide Commercial OperationsView
Robin Washington, CFO and Executive VPView
Norbert Bischofberger, Chief Scientific Officer and Executive VP of RandDView
Per WoldOlsen, Independent DirectorView
Harish Manwani, DirectorView
Taiyin Yang, Executive Vice President - Pharmaceutical Development and ManufacturingView
Kevin Young, COOView
Etienne Davignon, Independent DirectorView
Richard Whitley, Independent DirectorView

Stock Performance Indicators

Current Sentiment - GILD

Gilead Sciences Investor Sentiment

Majority of Macroaxis users are currently bullish on Gilead Sciences. What is your judgment towards investing in Gilead Sciences? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please check Risk vs Return Analysis. Please also try Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page